Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a/b study of DDY391 in Sjögren's disease
NL-OMON61730Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Sjögren's syndrome comparing DDY391 with Placebo (2 arms). Primary endpoints: Part A: Change from baseline in EULAR Sjögren's Syndrome Disease Activity Index, Part B: Change from baseline in EULAR Sjögren's Syndrome Disease Activity Index and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
DDY391
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON61730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61730.